tgen | Strategic Alliance Partners

Joseph Mikhael, MD, discusses remaining challenges in high-risk multiple myeloma.

Joseph Mikhael, MD, discusses unmet needs in triple-class refractory multiple myeloma.

Jeffrey M. Trent, MD, president and research director, Translational Genomics Research Institute, discusses the Stand Up to Cancer-Melanoma Research Alliance Dream Team.

$12 million in grants pursued by TGen-George Mason Molecular Medicine Alliance, leveraging institutes' expertise in genomics and proteomics.

Ramesh K. Ramanathan, MD, describes a phase II study that analyzed gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer.

The addition of albumin-bound paclitaxel (nab-paclitaxel; Abraxane) to standard treatment with gemcitabine significantly lengthens survival in patients with metastatic pancreatic cancer, researchers report.

The ability of clinicians to improve treatment outcomes that gemcitabine offers for patients with metastatic pancreatic cancer is expected to move forward now that the FDA has approved a new indication for nab-paclitaxel (Abraxane) as part of a combination regimen, according to researchers.

The FDA has approved nab-paclitaxel plus gemcitabine as a first-line treatment for patients with metastatic adenocarcinoma of the pancreas, an area of high unmet need with few effective treatments.

The FDA has granted priority review to nab-paclitaxel in combination with gemcitabine for the first-line treatment of patients with metastatic pancreatic cancer.